Affordable Access

Access to the full text

The Antibody Society’s antibody validation webinar series

  • Voskuil, Jan L.A.1
  • Bandrowski, Anita2
  • Begley, C. Glenn3
  • Bradbury, Andrew R.M.4
  • Chalmers, Andrew D.5, 6
  • Gomes, Aldrin V.7
  • Hardcastle, Travis8
  • Lund-Johansen, Fridtjof9
  • Plückthun, Andreas10
  • Roncador, Giovanna11
  • Solache, Alejandra12
  • Taussig, Michael J.13
  • Trimmer, James S.14
  • Williams, Cecilia15, 16
  • Goodman, Simon L.17
  • 1 Aeonian Biotech Ltd, UK
  • 2 University of California, USA
  • 3 BioCurate, Australia , (Australia)
  • 4 Specifica Inc, USA
  • 5 University of Bath, UK
  • 6 CiteAb, UK
  • 7 University of California Davis, USA
  • 8 Horizon Discovery, UK
  • 9 Oslo University Hospital, Norway , (Norway)
  • 10 University of Zurich, Switzerland , (Switzerland)
  • 11 Spanish National Cancer Research Center, Spain , (Spain)
  • 12 Abcam Plc, Discovery Drive, Cambridge Biomedical Campus, UK
  • 13 Cambridge Protein Arrays Ltd., Babraham Research Campus, UK
  • 14 University of California Davis School of Medicine, USA
  • 15 KTH Royal Institute of Technology, Sweden , (Sweden)
  • 16 Karolinska Institutet, Sweden , (Sweden)
  • 17 The Antibody Society, Inc, USA
Published Article
Landes Bioscience
Publication Date
Aug 04, 2020
DOI: 10.1080/19420862.2020.1794421
PMID: 32748696
PMCID: PMC7531563
PubMed Central


In the wake of the reproducibility crisis and numerous discussions on how commercially available antibodies as research tool contribute to it, The Antibody Society developed a series of 10 webinars to address the issues involved. The webinars were delivered by speakers with both academic and commercial backgrounds. This report highlights the problems, and offers solutions to help the scientific community appropriately identify the right antibodies and to validate them for their research and development projects. Despite the various solutions proposed here, they must be applied on a case-by-case basis. Each antibody must be verified based on the content of the product sheet, and subsequently through experimentation to confirm integrity, specificity and selectivity. Verification needs to focus on the precise application and tissue/cell type for which the antibody will be used, and all verification data must be reported openly. The various approaches discussed here all have caveats, so a combination of solutions must be considered.

Report this publication


Seen <100 times